Figure S5 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil; Maxime Fredon; Nawfel Adib; Adeline Bouard; Marie Perchaud; Syrine Abdeljaoued; Charles-Frédéric Mantion; Kamal Asgarov; Philippe Guillaume; Laurie Spehner; Evan Seffar; Marjorie Labesse; Angélique Vienot; Virginie Mougey; Mathieu Gonçalves-Venturelli; Sara Bobisse; Alexandre Harari; Camilla Jandus; Francine Garnache‐Ottou; Delphine Binda; Olivier Adotévi; Yann Godet; Marie Kroemer; Christophe Borg; Romain Loyon

doi:10.1158/2326-6066.31024190

Figure S5 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

2026 Open access

Read full text

Authors: Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard, Marie Perchaud, Syrine Abdeljaoued, Charles-Frédéric Mantion, Kamal Asgarov, Philippe Guillaume, Laurie Spehner, Evan Seffar, Marjorie Labesse

+13 more

Angélique Vienot, Virginie Mougey, Mathieu Gonçalves-Venturelli, Sara Bobisse, Alexandre Harari, Camilla Jandus, Francine Garnache‐Ottou, Delphine Binda, Olivier Adotévi, Yann Godet, Marie Kroemer, Christophe Borg, Romain Loyon

DOI: 10.1158/2326-6066.31024190

Cited by: 0

Abstract

SALL4-TCR redirected T cells recognize and kill S9V preloaded MDA-MB231 cell line (positive control). Representative graphs of Mock or SALL4-TCR T cells cocultured during 2 days with MDA-MB231 cell line preloaded with S9V peptide. (A) In vitro lysis kinetics obtained by red cytotox (left) and green signal (right) measurements on S9V preloaded MDA-MB231 during 2 days coculture in the presence of Mock (orange) or SALL4-TCR T cells (blue) measured by live-cell imaging IncuCyte. E:T ratio 10:1. Data represent mean ± SD of triplicates, statistics were calculated on the 3000 min time point. ***p

Fields of Study & Subjects

Renal and related cancers CAR-T cell therapy research Immunotherapy and Immune Responses

Publication details

Publication date: 8 January 2026